Second-generation antipsychotic long-acting injections in bipolar disorder: Systematic review and meta-analysis by Prajapati, Asta R. et al.
Bipolar Disorders. 2018;1–10.	 wileyonlinelibrary.com/journal/bdi	 | 	1
 
Received:	19	January	2018  |  Revised:	20	July	2018  |  Accepted:	30	September	2018
DOI: 10.1111/bdi.12707
R E V I E W  A R T I C L E
Second‐generation antipsychotic long‐acting injections in 
bipolar disorder: Systematic review and meta‐analysis
































over	 placebo	 for	 study‐defined	 relapse	 rate	 (RR	=	0.58,	 95%	 CI	=	0.49‐0.68,	
P	<	0.00001)	 and	 all‐cause	 discontinuation	 (RR	=	0.72,	 95%	 CI	=	0.64‐0.82,	
P	<	0.00001).	However,	no	significant	difference	was	found	between	SGA	LAIs	and	
oral	active	control	for	relapse	rate	(RR	=	0.92,	P	=	0.79)	and	all‐cause	discontinuation	
(RR	=	1.2,	P	=	0.31).	 In	 terms	of	 secondary	outcomes,	 SGA	LAIs	 performed	better	
than	placebo	in	relapse	to	mania/hypomania,	young	mania	rating	scales	(YMRS),	clini‐
cal	global	 impression‐severity	 (CGI‐S),	montgomery‐asberg	depression	 rating	scale	














functioning.1‐3	 However,	 about	 40%	 of	 people	 with	 bipolar	 disor‐
der	do	not	adhere	to	their	prescribed	treatment.	Non‐adherence	is	
associated	with	increased	risk	of	relapse	and	suicide,	unfavourable	
outcomes,	 and	 admission	 to	 hospital.	 The	 probability	 of	 hospital‐
isation	 is	 five	 times	 or	 higher	 in	 non‐adherent	 patients	 compared	
to	 adherent	patients	with	bipolar	disorder.4	 Long‐acting	 injections	
(LAIs,	 also	known	as	depots)	may	 improve	adherence	and	 thereby	
patient	outcomes.	Evidence	from	studies	in	people	with	schizophre‐
nia	 suggests	 that	 antipsychotic	 LAIs	 reduce	 relapses,	 medication	
discontinuation	 rates,	 and	 admission	 to	 hospital	 compared	 to	 oral	
antipsychotics.5‐7	LAIs	have	some	clear	advantages	including	assur‐
ance	of	medication	administration	and	the	opportunity	to	intervene	






although	 risperidone	 LAI	 and	more	 recently	 aripiprazole	 LAI	 have	
been	approved	in	the	US,	Canada,	and	Australia	for	bipolar	disorder.	
However,	evidence	base	for	efficacy	is	conflicting.3,12‐14	This	meta‐
analysis	 of	 RCTs	 (≥6	months	 duration)	 sought	 to	 address	whether	
there	is	sufficient	evidence	to	recommend	SGA	LAIs	in	patients	with	
bipolar	 disorder	 compared	 to	 placebo	 and	 active	 control.	 To	 our	









The	 study	 eligibility	 criteria	 were	 based	 on	 the	 PICOS	 framework;	
Participants,	Interventions,	Comparators,	Outcomes,	and	Study	design.











o	 Secondary	 outcomes	 included	 relapse	 to	 mania/hypomania,	
relapse	to	depression,	changes	 in	young	mania	rating	scales,	
montgomery‐asberg	 depression	 rating	 scale,	 clinical	 global	





2.2 | Data sources, search strategy, and 
study selection
The	following	search	strategy	was	employed	to	ensure	all	relevant	stud‐














b	 Treatment:	 antipsychotic*,	 neuroleptic*,	 psychotropic*,	 atypical*,	
second	 generation	 antipsychotic*,	 SGA*,	 aripiprazole,	 olanzapine,	
paliperidone,	risperidone,	AND
c	 Formulation:	depot*,	 long‐acting	 inject*,	LAI*,	prolonged	release	
inject*,	sustained	release	inject*
The	process	of	identifying,	screening	of	studies,	and	inclusion	
or	 exclusion	of	 those	 studies	 is	 shown	 in	 the	PRISMA	 flow	dia‐
gram	below	(see	Figure	1).
K E Y W O R D S
antipsychotic	depots,	antipsychotic	long‐acting	injection,	bipolar	disorder,	mental	health,	
meta‐analysis,	second‐generation	antipsychotic
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A	 total	 of	 645	 studies	were	 found.	 The	 result	 from	each	 stage	of	
screening	is	shown	in	Prisma	flow	diagram	(See	Figure	1).




F I G U R E  1  PRISMA	flow	diagram	of	
studies





For	 the	 meta‐analysis,	 studies	 were	 categorised	 into	 placebo	




cebo‐controlled	 category	while	 risperidone	 LAI	 vs	 oral	 olanzapine	
(Vieta,	2012	A)	under	active	controlled.
a	 Study‐defined	 relapse	 rate	 (placebo‐controlled	 studies	 only):	
Pooled	 data	 from	 four	 placebo‐controlled	 studies	 favour	 SGA	
LAIs	for	study‐defined	relapse	rate	as	shown	in	Figure	2	with	sta‐
tistically	significant	difference	between	the	two	groups.




c	 Primary	efficacy	outcome:	Study‐defined	 relapse	 rate	 (active‐con‐
trolled	 studies	 only).	 Active‐controlled	 studies	 evaluated	 various	
oral	 antipsychotics	 or	 TAU	 against	 risperidone	 LAI.	 There	was	 no	






weighted	study	with	 two	 third	of	participants.	Thus,	 the	study	by	
Vieta	et	al	was	retained	in	the	analysis.
d	 All‐cause	discontinuation	(Active‐controlled	studies	only).	All‐cause	
discontinuation	was	 not	 significantly	 different	 between	 SGA	 LAIs	
group	and	active	control	group	as	shown	in	Figure	5	below.
3.3 | Sensitivity and subgroup analysis
We	 conducted	 sensitivity	 analysis	 excluding	 low‐quality	 studies	 (ie,	
Jadad	 score	 <4)	 for	 study‐defined	 relapse	 rate.	 Active	 control	 out‐
performed	SGA	LAI	 (n	=	261,	RR	=	1.63,	95%	CI	=	1.12‐2.37,	P	=	0.01,	





TA B L E  1  Summary	of	studies	included	in	meta‐analysis
Study (Ref) Study design No. of Participants No. completed study




















F I G U R E  2  Study‐defined	relapse	rate	(placebo‐controlled	studies	only)
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vs	 non‐rapid	 cycling—for	 study‐defined	 relapse	 rates	 in	 placebo‐
controlled	and	active‐controlled	studies.
Placebo‐controlled	 studies	 show	 SGA	 LAIs	 better	 than	 placebo	
both	as	an	adjunctive	 (RR	=	0.5,	95%	CI	=	0.3‐0.85,	P	=	0.01)	and	as	
monotherapy	(RR	=	0.58,	95%	CI	=	0.49‐0.69,	P	<	0.00001).	However,	
active	 control	 performed	 better	 than	 SGA	 LAIs	 as	 monotherapy	




but	 active	 control	 performed	 better	 than	 SGA	 LAIs	 (RR	=	1.63,	 95%	
CI	=	1.12‐2.37,	 P	=	0.01).	 Three	 open‐label	 studies3,17,18	 show	 SGA	
LAIs	 performing	 better	 than	 active	 control	 (n	=	133,	 RR	=	0.70,	 95%	
CI	=	0.53‐0.94,	P	=	0.02).
Studies	in	patients	with	rapid	cycling	bipolar	disorder	show	statis‐
tically	 significant	 improvement	with	 SGA	 LAIs	 compared	 to	 placebo	
(n	=	1RCT)	and	active	control	 (n	=	1RCT).	 In	nonrapid	cycling	studies,	
SGA	 LAI	 were	 superior	 to	 placebo	 (RR	=	0.58,	 95%	 CI	=	0.49‐0.69,	
P	<	0.00001)	 but	 not	 active	 control	 (RR	=	1.29,	 95%	 CI	=	0.97‐1.29,	
P	=	0.08).
3.4 | Secondary outcome measures
Secondary	 outcome	measures	 were	 analysed	 similar	 to	 the	 pri‐







regarding	 relapse	 to	mania/hypomania,	 YMRS,	CGI‐S,	 EPSEs,	weight	
gain.	However,	the	active	control	performed	better	than	SGA	LAIs	in	
relapse	 to	depression,	MADRS,	 and	prolactin‐related	AEs.	These	are	
F I G U R E  3  All‐cause	discontinuation	(placebo‐controlled	studies	only)
F I G U R E  4  Study‐defined	Relapse	rate	(active‐controlled	studies	only)
F I G U R E  5  All‐cause	discontinuation	(active‐controlled	studies	only)
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TA B L E  2  Meta‐analysis	result	for	secondary	outcome	measures
Outcome
No. of
Effect size 95% CI I2 P‐valueRCTs Patients
PC:	Relapse	to	mania/
hypomania
4 929 RR	=	0.39 0.30	to	0.51 0% <0.00001
AC:	Relapse	to	mania/
hypomania
2 300 RR	=	0.83 0.29	to	2.36 80% 0.72
PC:	Relapse	to	depression 4 929 RR	=	1.07 0.79	to	1.45 0% 0.67
AC:	Relapse	to	depression 2 300 RR	=	1.83 1.05	to	3.19 0% 0.03
PC:	YMRS 4 922 MD	=	−5.05 −6.27	to	−3.84 0% <0.00001
AC:	YMRS 4 394 MD	=	−0.04 −1.41	to	1.33 0% 0.96
PC:	MADRS 3 656 MD	=	−1.55 −2.86	to	–0.25 0% 0.02
AC:	MADRS 3 345 MD	=	2.2 0.52	to	3.88 0% 0.01
PC:	CGI‐S 3 656 MD	=	−0.77 −1.01	to	−0.53 0% <0.00001
AC:	CGI‐S 4 394 MD	=	0.05 −0.39	to	0.49 59% 0.82
PC:	Discontinuation	due	to	AEs 4 929 RR	=	2.89 1.03	to	8.09 0% 0.04
AC:	Discontinuation	due	to	AEs 4 403 RR	=	1.63 0.6	to	4.45 0% 0.34
PC:	EPSEs 3 693 RR	=	1.69 1.16	to	2.45 0% 0.006
AC:	EPSEs 2 84 RR	=	1.06 0.43	to	2.65 0% 0.9
PC:	Weight	gain 4 960 RR	=	2.32 1.33	to	4.06 40% 0.003
AC:	Weight	gain 3 347 RR	=	0.86 0.59	to	1.26 0% 0.44
PC:	Prolactin	related	AEs 3 694 RR	=	3.43 1.13	to	10.39 37% 0.03
AC:	Prolactin	related	AEs 3 347 RR	=	5.75 2.03	to	16.29 0% 0.0010
AEs,	adverse	effects;	RR,	risk	ratio;	MD,	mean	difference.
TA B L E  3  Quality	assessment	of	studies	included	in	meta‐analysis
Questions Calabrese16 Bobo 17 Chengappa 18 Macfadden19 Quiroz 21 Vieta 20 Yatham 3
1.	Was	the	study	described	as	ran‐
domised?	Yes	=	1,	No	=	0




1 1 0 1 1 1 1
3.	Was	the	study	described	as	double	
blind?	Yes	=	1,	No	=	0




1 0 0 1 1 1 0
5.	Was	there	a	description	of	withdrawals	
and	dropouts?	Yes	=	1,	No	=	0












0 0 0 0 0 0 0
Total Jadad Score 5 3 2 5 4 5 3




3.5 | Quality Assessment of Studies




No	 attrition	 or	 reporting	 bias	 was	 noted	 within	 individual	



















It	 is	 also	 argued	 that	 participants	 in	 the	 RCTs	 are	more	 likely	 to	



























4.3 | Strengths and limitations of the study






















Cochrane	 does	 not	 recommend	 the	 use	 of	 scales	 for	 quality	 or	
risk	assessment.	However,	the	Jadad	scale	is	well	known,	simple,	and	
F I G U R E  6  Funnel	plot	of	all	active‐	and	placebo‐controlled	
studies










































depression.13,22	Another	 reason	to	exclude	FGA	LAIs	 is	 that	patients	
with	bipolar	disorder	may	be	more	at	risk	of	EPSEs,	for	example,	when	
























pleteness	 of	 the	 search.	 In	 addition	 to	 databases	 searched	 by	 Kishi	
et	 al	 (Medline,	 Cochrane	 Library,	 PsycINFO,	 Clinicaltrials.gov),	 we	
also	searched	LiLACS	(to	cover	literature	from	Latin	America	and	the	
Caribbean	which	may	not	have	been	covered	elsewhere),	EMBASE,	and	
CINAHL	 (to	 cover	 allied	 health	 professional	 literature).	 Furthermore,	
we	also	contacted	manufacturers	of	SGA	LAIs	for	further	published	or	
unpublished	studies	which	were	lacking	in	the	previous	meta‐analysis.


























Further	 studies,	 particularly	 high‐quality	 active‐controlled	 stud‐
ies,	 are	warranted	 for	 conclusive	evidence.	There	are	 four	SGA	LAIs	










nificant	 logistical	 issues	due	to	the	post	 injection	syndrome	and	thus	
requiring	patients	to	be	observed	for	3‐hour	post	injection.	This	may	be	
a	significant	barrier	to	prescribing	as	well	as	any	future	research.
4.6 | Cost and policy implication
Future	 research	would	benefit	 from	 incorporating	 cost‐effectiveness	
analysis.	 It	 is	often	argued	 that	LAIs	 reduce	 relapse	and	 thus	 reduce	
healthcare	cost;	however,	this	meta‐analysis	shows	no	significant	dif‐
ference	 in	 study‐defined	 relapse	 rate	when	 SGA	LAIs	 are	 compared	
with	active	control.	The	cost	of	SGA	LAIs	is	significantly	more	than	the	



























lar	 patients	 with	 known	 adherence	 problems	 with	 oral	 medication.	
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